drugset / Trial / NCT03414008

This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated

NCT03414008

Phase 1 Terminated 54 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The primary objective of this trial is to investigate the safety and tolerability of BI 1291583 in healthy male subjects following oral administration of single rising doses. Secondary objectives are the exploration of the pharmacokinetics (PK) including dose proportionality and pharmacodynamics (PD) of BI 1291583 after single dosing.

Timeline

Start
2018-02-05
Primary completion
2019-11-18
Completion
2019-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown Oral

Indications

No indication recorded.